Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)GlobeNewsWire • 10/20/21
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVNNewsfile Corp • 10/19/21
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVNNewsfile Corp • 10/15/21
Longeveron to Present at the 2021 Dawson James Securities 6th Annual Small Cap Growth ConferenceGlobeNewsWire • 10/14/21
ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVNPRNewsWire • 10/13/21
LGVN SHAREHOLDER CLASS ACTION FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc.Newsfile Corp • 10/12/21
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVNBusiness Wire • 10/09/21
LONGEVERON INC. (LGVN) SHAREHOLDER LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc.Newsfile Corp • 10/07/21
ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors With Losses to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVNPRNewsWire • 10/06/21
LONGEVERON INC. (NASDAQ: LGVN) INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc.PRNewsWire • 10/05/21
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 10/04/21
Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry SegmentBenzinga • 10/04/21
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors With Losses Over $100K to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVNNewsfile Corp • 10/01/21
LGVN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Longeveron Inc. Investors of Class Action and Encourages Shareholders to Contact the FirmNewsfile Corp • 10/01/21
LGVN Notice: Rosen, a Global and Leading Law Firm, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - LGVNNewsfile Corp • 09/29/21
Longeveron Announces Potential Biomarker Correlating with Lomecel-B BioactivityGlobeNewsWire • 09/29/21
Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia ResearchGlobeNewsWire • 09/28/21
LONGEVERON INC. (LGVN) INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc.Newsfile Corp • 09/27/21
ROSEN, A TOP RANKED FIRM, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 21 Deadline in Securities Class Action - LGVNNewsfile Corp • 09/25/21
LGVN Investor Notice: Rosen, Trusted Investor Counsel, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - LGVNNewsfile Corp • 09/23/21
LGVN SHAREHOLDER LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc.Newsfile Corp • 09/21/21
Longeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia ResearchGlobeNewsWire • 09/21/21
